Protagenic Therapeutics Stock Net Asset
| PTIXW Stock | USD 0.01 0 11.11% |
Protagenic Therapeutics fundamentals help investors to digest information that contributes to Protagenic Therapeutics' financial success or failures. It also enables traders to predict the movement of Protagenic Stock. The fundamental analysis module provides a way to measure Protagenic Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Protagenic Therapeutics stock.
Protagenic | Net Asset |
Protagenic Therapeutics Company Net Asset Analysis
Protagenic Therapeutics' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Protagenic Therapeutics Net Asset | 4.32 M |
Most of Protagenic Therapeutics' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Protagenic Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Protagenic Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Protagenic Therapeutics is extremely important. It helps to project a fair market value of Protagenic Stock properly, considering its historical fundamentals such as Net Asset. Since Protagenic Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Protagenic Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Protagenic Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionProtagenic Total Assets
Total Assets |
|
Based on the recorded statements, Protagenic Therapeutics has a Net Asset of 4.32 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Protagenic Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Protagenic Therapeutics' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Protagenic Therapeutics could also be used in its relative valuation, which is a method of valuing Protagenic Therapeutics by comparing valuation metrics of similar companies.Protagenic Therapeutics is currently under evaluation in net asset category among its peers.
Protagenic Fundamentals
| Return On Equity | -2.06 | ||||
| Return On Asset | -0.9 | ||||
| EBITDA | (4.5 M) | ||||
| Net Income | (5 M) | ||||
| Cash And Equivalents | 671.09 K | ||||
| Cash Per Share | 0.06 X | ||||
| Total Debt | 655.25 K | ||||
| Current Ratio | 1.34 X | ||||
| Book Value Per Share | 0.83 X | ||||
| Cash Flow From Operations | (3.7 M) | ||||
| Beta | 0.25 | ||||
| Total Asset | 4.32 M | ||||
| Retained Earnings | (30.78 M) | ||||
| Working Capital | 3.54 M | ||||
| Net Asset | 4.32 M |
About Protagenic Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Protagenic Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Protagenic Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Protagenic Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Protagenic Stock Analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.